Related Experiment Video
Updated: Dec 12, 2025

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
[Mesogastric desmoid tumor, a rare entity]
L Lapaille1, E Mutijima2, C Loly3
1Faculté de Médecine, ULiège, Belgique.
Desmoid tumors, or aggressive fibromatosis, are rare, locally invasive soft tissue tumors with a high recurrence risk. Differentiating them from malignancy recurrence after surgery requires careful consideration and close monitoring.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Desmoid tumors, also known as aggressive fibromatosis, are rare soft tissue neoplasms.
- They are characterized by local invasiveness and a high tendency for recurrence, but do not metastasize.
- Etiology involves sporadic somatic CTNNB1 gene mutations, trauma, surgery, or pregnancy.
Observation:
- These tumors commonly occur in extra-abdominal locations but can also arise in the abdominal wall, mesentery, or retroperitoneum.
- Distinguishing desmoid tumors from local malignancy recurrence after intra-abdominal surgery can be challenging during follow-up.
- Desmoid tumors should be included in the differential diagnosis, particularly in patients with a history of surgery.
Findings:
- The clinical behavior, local invasiveness, and recurrence potential are critical factors in therapeutic decision-making.
- A conservative management strategy is often warranted.
- This approach necessitates rigorous clinical and radiological surveillance.
Implications:
- Accurate diagnosis is crucial for appropriate patient management.
- Understanding the differential diagnosis aids in avoiding misdiagnosis of malignancy recurrence.
- Conservative treatment with close monitoring may be a viable strategy for managing desmoid tumors.
More Related Videos
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024